These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
868 related articles for article (PubMed ID: 33212758)
1. The Role of α-Synuclein Oligomers in Parkinson's Disease. Du XY; Xie XX; Liu RT Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212758 [TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Rocha EM; De Miranda B; Sanders LH Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134 [TBL] [Abstract][Full Text] [Related]
3. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083 [TBL] [Abstract][Full Text] [Related]
4. Role of α-synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease. Yu S; Chan P Essays Biochem; 2014; 56():125-35. PubMed ID: 25131591 [TBL] [Abstract][Full Text] [Related]
5. Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis. Gadhe L; Sakunthala A; Mukherjee S; Gahlot N; Bera R; Sawner AS; Kadu P; Maji SK Biophys Chem; 2022 Feb; 281():106736. PubMed ID: 34923391 [TBL] [Abstract][Full Text] [Related]
6. Modulating α-synuclein propagation and decomposition: Implications in Parkinson's disease therapy. Li B; Xiao X; Bi M; Jiao Q; Chen X; Yan C; Du X; Jiang H Ageing Res Rev; 2024 Jul; 98():102319. PubMed ID: 38719160 [TBL] [Abstract][Full Text] [Related]
8. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease. Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886 [TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease. Zhang YN; Fan JK; Gu L; Yang HM; Zhan SQ; Zhang H J Neuroinflammation; 2021 Jan; 18(1):23. PubMed ID: 33461598 [TBL] [Abstract][Full Text] [Related]
10. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
11. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease. Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450 [TBL] [Abstract][Full Text] [Related]
12. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232 [TBL] [Abstract][Full Text] [Related]
13. β-Synuclein Intermediates α-Synuclein Neurotoxicity in Parkinson's Disease. Xian M; Li J; Liu T; Hou K; Sun L; Wei J ACS Chem Neurosci; 2024 Jul; 15(13):2445-2453. PubMed ID: 38905183 [TBL] [Abstract][Full Text] [Related]
14. Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease. Hu Q; Uversky VN; Huang M; Kang H; Xu F; Liu X; Lian L; Liang Q; Jiang H; Liu A; Zhang C; Pan-Montojo F; Zhu S Biochim Biophys Acta; 2016 Oct; 1862(10):1883-90. PubMed ID: 27425033 [TBL] [Abstract][Full Text] [Related]
15. α-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson's disease. Zalon AJ; Quiriconi DJ; Pitcairn C; Mazzulli JR Neuroscientist; 2024 Oct; 30(5):612-635. PubMed ID: 38420922 [TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract. Shaltiel-Karyo R; Davidi D; Frenkel-Pinter M; Ovadia M; Segal D; Gazit E Biochim Biophys Acta; 2012 Oct; 1820(10):1628-35. PubMed ID: 22575665 [TBL] [Abstract][Full Text] [Related]
17. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596 [TBL] [Abstract][Full Text] [Related]
18. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers. Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040 [TBL] [Abstract][Full Text] [Related]
19. Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease. He S; Zhong S; Liu G; Yang J Neurodegener Dis; 2020; 20(2-3):55-64. PubMed ID: 33465773 [TBL] [Abstract][Full Text] [Related]